Evidence map›Paper›PMID 11444526›Full record

ArticleGene expression2001

Responsiveness to transforming growth factor-beta (TGF-beta)-mediated growth inhibition is a function of membrane-bound TGF-beta type II receptor in human breast cancer cells.

M A Lynch, T A Petrel, H Song, T J Knobloch, B C Casto, D Ramljak, L M Anderson, V DeGroff, G D Stoner, R W Brueggemeier and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Gene expression, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

M A LynchDivision of Environmental Health Sciences, School of Public Health, College of Medicine and Public Health, The Ohio State University, Columbus 43210, USA.
T A Petrel
H Song
T J Knobloch
B C Casto
D Ramljak
L M Anderson
V DeGroff
G D Stoner
R W Brueggemeier
C M Weghorst
The Ohio State University · USNational Cancer Institute · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
TGF BETA RECEPTOR COMPLEX IN ORAL CANCER DEVELOPMENTP01DE012704 · NIDCR · OHIO STATE UNIVERSITY · PI STONER, GARY D · 1998 to 2002
$3.0M
MOLECULAR MECHANISMS OF ORAL CANCER DEVELOPMENTR01DE011943 · NIDCR · OHIO STATE UNIVERSITY · PI WEGHORST, CHRISTOPHER M · 1998 to 2002
$503k
PROGRAM DEVELOPMENT GRANT ON BREAST CANCERR21CA066193 · NCI · OHIO STATE UNIVERSITY · PI BRUEGGEMEIER, ROBERT W · 1994 to 1997
–
NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA16058NCI NIH HHS R21 CA66193NIDCR NIH HHS 1PO1 DE12704NIDCR NIH HHS P01 DE012704NIDCR NIH HHS R01 DE011943
6 · The paper itself

Abstract

Transforming growth factor-beta (TGF-beta) is a potent inhibitor of growth and proliferation of breast epithelial cells, and loss of sensitivity to its effects has been associated with malignant transformation and tumorigenesis. The biological effects of TGF-beta are mediated by the TGF-beta receptor complex, a multimer composed of TGF-beta receptor type I (TbetaR-I) and TGF-beta receptor type II (TbetaR-II) subunits. Evidence suggests that loss of expression of Tbeta3R-II is implicated in the loss of sensitivity of tumorigenic breast cell lines to TGF-beta-mediated growth inhibition. A panel of human breast cell lines, including the immortalized MCF-10F and tumorigenic MCF-7, ZR75-1, BT474, T47-D, MDA-MB231, BT20, and SKBR-3 cell lines, was characterized for responsiveness to TGF-beta-induced G1 growth arrest. Only the nontumorigenic MCF-10F and the tumorigenic MDA-MB231 cell lines demonstrated a significant inhibitory response to TGF-beta1 and a significant binding of 125I-labeled TGF-beta ligand. While expression of TbetaR-I mRNA was similar across the panel of cell lines, TbetaR-II mRNA expression was decreased significantly in all seven tumorigenic cell lines in comparison with the nontumorigenic MCF- 10F cell line. When total cellular protein was fractionated by centrifugation, TbetaR-I protein was observed in both the cytosolic and membrane fractions at similar levels in all cell lines; however, TbetaR-II protein was present in the cytosolic fraction in all cell lines, but was observed in the membrane fraction of only the TGF-beta-responsive MCF-10F and MDA-MB231 cells. Thus, lack of membrane-bound TbetaR-II protein appears to be an important determinant of resistance to TGF-beta-mediated growth inhibition in this group of breast cell lines.

Indexed as

Blotting, WesternBreast NeoplasmsCell DivisionDNA Mutational AnalysisDose-Response Relationship, DrugDrug Resistance, NeoplasmFemaleG1 PhaseHumansMutationProtein Serine-Threonine KinasesProtein SubunitsReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type IIReverse Transcriptase Polymerase Chain ReactionRNA, MessengerProtein Serine-Threonine KinasesProtein SubunitsReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type IIRNA, MessengerTransforming Growth Factor beta

Identifiers

PMID11444526
PMCPMC5964939
OpenAlexW2399257279

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.